A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...
Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help ...
Background: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH). Recently, fenfluramine appetite suppressants became widely ...
Frespaciguat is under clinical development by Merck and currently in Phase III for Idiopathic Pulmonary Hypertension. According to GlobalData, Phase III drugs for Idiopathic Pulmonary Hypertension ...
Frespaciguat is under clinical development by Merck and currently in Phase II for Pulmonary Hypertension. According to GlobalData, Phase II drugs for Pulmonary Hypertension have a 58% phase transition ...